Cancer of Unknown Primary in the Molecular Era.

Abstract:

:Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation sequencing has revealed genomic alterations that can be targeted in selected cases, suggesting that CUP represents a unique malignancy in which the genomic aberrations may be integral to the diagnosis. Recent trials focusing on tailored combination therapy matched to the genomic alterations in each cancer are providing new avenues of clinical investigation. Here, we discuss recent findings on molecular aberrations in CUP and how the genomic and immune landscape can be leveraged to optimize therapy.

journal_name

Trends Cancer

journal_title

Trends in cancer

authors

Kato S,Alsafar A,Walavalkar V,Hainsworth J,Kurzrock R

doi

10.1016/j.trecan.2020.11.002

subject

Has Abstract

pub_date

2021-01-27 00:00:00

eissn

2405-8033

issn

2405-8025

pii

S2405-8033(20)30301-0

pub_type

杂志文章,评审
  • DUBs, Hypoxia, and Cancer.

    abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.08.005

    authors: Mennerich D,Kubaichuk K,Kietzmann T

    更新日期:2019-10-01 00:00:00

  • Noninvasive PET Imaging of T cells.

    abstract::The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.03.009

    authors: Wei W,Jiang D,Ehlerding EB,Luo Q,Cai W

    更新日期:2018-05-01 00:00:00

  • Cadherins Glycans in Cancer: Sweet Players in a Bitter Process.

    abstract::Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.08.003

    authors: Carvalho S,Reis CA,Pinho SS

    更新日期:2016-09-01 00:00:00

  • Thermoneutrality, Mice, and Cancer: A Heated Opinion.

    abstract::The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.03.005

    authors: Hylander BL,Repasky EA

    更新日期:2016-04-01 00:00:00

  • A Molecular Take on Malignant Rhabdoid Tumors.

    abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.04.003

    authors: Tang M,Verhaak RG

    更新日期:2016-05-01 00:00:00

  • The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity.

    abstract::Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immuno...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.09.001

    authors: Böttcher JP,Reis e Sousa C

    更新日期:2018-11-01 00:00:00

  • The Emerging Role of ABL Kinases in Solid Tumors.

    abstract::The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.07.004

    authors: Wang J,Pendergast AM

    更新日期:2015-10-01 00:00:00

  • Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

    abstract::Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.007

    authors: Yang Z,Gimple RC,Zhou N,Zhao L,Gustafsson JÅ,Zhou S

    更新日期:2020-12-16 00:00:00

  • Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

    abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.07.005

    authors: Jetten AM

    更新日期:2019-09-01 00:00:00

  • Are Microbial Endophytes the 'Actual' Producers of Bioactive Antitumor Agents?

    abstract::For millenia, plants have been a major source of medications against human and animal diseases. In the case of anticancer agents, a significant number of current agents can trace their source back to nominally plant secondary metabolites, with examples being taxol, vinca alkaloids, camptothecin (CPT), and their modifi...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.08.002

    authors: Newman DJ

    更新日期:2018-10-01 00:00:00

  • PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy.

    abstract::Targeted therapy has become increasingly important in cancer therapy. For example, targeting the promyelocytic leukemia PML protein in leukemia has proved to be an effective treatment. PML is the core component of super-assembled structures called PML nuclear bodies (NBs). Although this nuclear megaDalton complex was ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.05.005

    authors: Li Y,Ma X,Wu W,Chen Z,Meng G

    更新日期:2020-10-01 00:00:00

  • Exit Stage Left: A Tumor Cell's Journey from Lymph Node to Beyond.

    abstract::Even though we have known for over 250 years that cancers spread to regional lymph nodes (LNs) and distant organs, the fundamental question of which anatomical routes are taken by tumor cells has remained a mystery. Two recently published papers in Science, by Pereira et al. and Brown et al., directly address this imp...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2018.05.007

    authors: Achen MG,Stacker SA

    更新日期:2018-08-01 00:00:00

  • Immunity Gone Astray - NETs in Cancer.

    abstract::Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2016.10.012

    authors: Cedervall J,Olsson AK

    更新日期:2016-11-01 00:00:00

  • Selective Targeting of RSK Isoforms in Cancer.

    abstract::The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.03.004

    authors: Casalvieri KA,Matheson CJ,Backos DS,Reigan P

    更新日期:2017-04-01 00:00:00

  • Microfluidics: A new tool for modeling cancer-immune interactions.

    abstract::In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.12.003

    authors: Boussommier-Calleja A,Li R,Chen MB,Wong SC,Kamm RD

    更新日期:2016-01-01 00:00:00

  • Transforming Biomarker Development with Exceptional Responders.

    abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.11.004

    authors: Jonsson P,Taylor BS

    更新日期:2018-01-01 00:00:00

  • Translin-Trax: Considerations for Oncological Therapeutic Targeting.

    abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.02.014

    authors: McFarlane RJ,Wakeman JA

    更新日期:2020-06-01 00:00:00

  • A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.

    abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.05.014

    authors: Gill J,Cetnar JP,Prasad V

    更新日期:2020-09-01 00:00:00

  • Advanced Prostate Cancer: Treatment Advances and Future Directions.

    abstract::Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.04.010

    authors: Swami U,McFarland TR,Nussenzveig R,Agarwal N

    更新日期:2020-08-01 00:00:00

  • Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

    abstract::The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.12.004

    authors: Subbiah V,Kurzrock R

    更新日期:2018-02-01 00:00:00

  • Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer.

    abstract::Obesity has been associated with increased severity of diagnoses for several types of cancer, and recent evidence suggests that the mechanism by which obese tissues contribute to cancer progression involves the extracellular matrix (ECM). Understanding the physicochemical differences between lean and obese ECM, and ho...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.02.001

    authors: Druso JE,Fischbach C

    更新日期:2018-04-01 00:00:00

  • The Hidden Conundrum of Phosphoinositide Signaling in Cancer.

    abstract::Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P3 from PI(4,5)P2 and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer research. However, PI(4,5)P2 is breaking its boundary as merely a substrate for PI3K an...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.05.009

    authors: Thapa N,Tan X,Choi S,Lambert PF,Rapraeger AC,Anderson RA

    更新日期:2016-07-01 00:00:00

  • TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

    abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.01.007

    authors: Shahbandi A,Nguyen HD,Jackson JG

    更新日期:2020-02-01 00:00:00

  • In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.07.002

    authors: Schneider G,Saur D

    更新日期:2016-08-01 00:00:00

  • Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

    abstract::Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.010

    authors: Lønning PE

    更新日期:2020-12-22 00:00:00

  • Connecting Timescales in Biology: Can Early Dynamical Measurements Predict Long-Term Outcomes?

    abstract::Prediction of long-term outcomes from short-term measurements remains a fundamental challenge. Quantitative assessment of signaling dynamics, and the resulting transcriptomic and proteomic responses, has yielded fundamental insights into cellular outcomes. However, the utility of these measurements is limited by their...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.12.008

    authors: Tsabar M,Lovitch SB,Jambhekar A,Lahav G

    更新日期:2021-01-12 00:00:00

  • Emerging Players in Prostate Cancer-Bone Niche Communication.

    abstract::Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts have been proposed as major contributors of osteotropism by PCa. Here, w...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.09.006

    authors: Furesi G,Rauner M,Hofbauer LC

    更新日期:2021-02-01 00:00:00

  • New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?

    abstract::Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.006

    authors: Slade DJ

    更新日期:2020-12-09 00:00:00

  • Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer.

    abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.11.008

    authors: Nizzero S,Shen H,Ferrari M,Corradetti B

    更新日期:2020-01-01 00:00:00

  • Repurposing Drugs in Oncology: Next Steps.

    abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2017.06.007

    authors: Verbaanderd C,Meheus L,Huys I,Pantziarka P

    更新日期:2017-08-01 00:00:00